Blog
RSS FeedPosted by Michael Wonder on 02 Oct 2018
Will USMCA affect Canada's drug prices? Depends on what happens next, experts say.
2 October 2018 - Trade deal extends 'data protection' period for expensive class of medicines to 10 years. ...
Posted by Michael Wonder on 22 Sep 2018
Ontario becomes first province to provide public funding of Tresiba for adults with diabetes mellitus
21 September 2018 - Manitoba to reimburse Tresiba following Ontario listing. ...
Posted by Michael Wonder on 10 Sep 2018
Canadian Dermatology Association and Canadian Society of Allergy and Clinical Immunology issue joint statement against the Canadian Agency for Drugs and Technologies in health recommendation
10 September 2018 - Many Canadian eczema sufferers are dealt a difficult blow; many patients face a future with no access ...
Posted by Michael Wonder on 09 Sep 2018
It's not just the EpiPen. Canada had 25 new drug shortages this week alone
8 September 2018 - Migraine and Parkinson's disease drugs and anesthetic among treatments added to drug shortage site. ...
Posted by Michael Wonder on 06 Sep 2018
We can make medicine affordable without the damage Pharmacare will cause Canadians
5 September 2018 - Governments should have public plans match the superior coverage offered in private drug plans and cover more ...
Posted by Michael Wonder on 30 Aug 2018
Renflexis (infliximab for injection) added to British Columbia's Provincial Drug Plan for all approved indications
22 August 2018 - Renflexis has been added to drug formulary for the treatment of adult and paediatric Crohn's disease and ...
Posted by Michael Wonder on 28 Aug 2018
Ottawa’s drug-pricing changes threaten Canadians who suffer from rare diseases
28 August 2018 - The federal government’s plan to increasingly regulate the costs of pharmaceuticals could mean Canadians with cystic ...
Posted by Michael Wonder on 09 Aug 2018
New from CADTH: Pharmaceutical Reviews Update
9 August 2018 - CADTH is pleased to announce the launch of its new Pharmaceutical Reviews Update newsletter. ...
Posted by Michael Wonder on 09 Aug 2018
David Agnew appointed Chair of the CADTH Board of Directors
8 August 2018 - CADTH is pleased to announce the appointment of Mr. David Agnew to Chair of the CADTH ...
Posted by Michael Wonder on 06 Aug 2018
Glatect, alternative to Copaxone, added to public health plans of 5 Canadian provinces
6 August 2018 - Pendopharm’s Glatect (glatiramer acetate injection), a lower cost alternative to Teva’s Copaxone, has been added to ...
Posted by Michael Wonder on 01 Aug 2018
Canada’s drug agency advised against reimbursing a costly eczema drug — here’s why people are worried
30 July 2018 - Five years ago, Felix Tang’s eczema was a debilitating accompaniment to stress. The chronic inflammatory skin ...
Posted by Michael Wonder on 24 Jul 2018
Cystic fibrosis patients launch class-action suit over access to costly drug
24 July 2018 - A young Victoria woman with cystic fibrosis who fought to get coverage of a life-changing drug ...
Posted by Michael Wonder on 24 Jul 2018
Debunking the myths about a Canadian pharmacare program
24 July 2018 - A national pharmacare program may one day be a reality in Canada. Myths abound about how it ...
Posted by Michael Wonder on 23 Jul 2018
Proposed PMPRB changes could limit Canada’s access to new drugs
20 July 2018 - While the federal government’s proposed amendments to Canada’s patented medicines regulations are aimed at reducing the ...
Posted by Michael Wonder on 10 Jul 2018
Sanofi denounces CADTH negative recommendation on Dupixent
10 July 2018 - Sanofi Genzyme said that it is disappointed with the recent recommendation by CADTH to not reimburse Dupixent, ...